BioSpace News Archive

Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed.

Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients

Frequency Therapeutics, Inc., a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference.

Phase 1 dose escalation and bioimaging study shows that ifabotuzumab demonstrates highly specific tumor targeting in patients with recurrent glioblastoma multiforme

Invitation to attend Vitrolife’s conference call regarding presentation of the interim report January - March 2021 . The presentation will be held in English. Time: Thursday 22 April, 2021 at 10.00 a.m. CET . Registration can preferably be done 10-15 minutes before the conference start time on: Sweden dial in number: +

Theralase® Technologies Inc. announced that it has executed a Collaborative Research Agreement with the National Microbiology Laboratory, Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featuring new data in patients with hidradenitis suppurativa (HS) from its non-interventional study of patients with HS or atopic dermatitis (AD)

• Bloom Burton & Co. Healthcare Investor Conference - April 21 st at 10:00 a.m. EST • • Planet MicroCap Showcase - April 22 nd at 10:00 a.m. EST •

Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, announced that Sandra Van Schaeybroeck, PhD (Queen’s University Belfast) will be presenting research supporting BOLD-100 as a potential anti-resistance therapy for difficult-to-treat cancers